Unveiling 13 Analyst Insights On Neurocrine Biosciences
Portfolio Pulse from Benzinga Insights
Over the past three months, 13 analysts have provided varied opinions on Neurocrine Biosciences (NASDAQ:NBIX), with recent ratings showing a shift towards a more bullish stance. The average 12-month price target is now $127.54, up from $121.70, with individual targets ranging from $100.00 to $150.00. Analysts have made adjustments to their ratings and price targets, reflecting changes in market conditions and company performance. Neurocrine Biosciences is a pharmaceutical company with late-stage clinical programs for CNS and endocrine-related conditions. Financial indicators show a positive revenue trend, high net margin, and strong ROE and ROA, with a low debt-to-equity ratio.
January 23, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have updated their ratings and price targets for Neurocrine Biosciences, indicating a bullish sentiment with an increased average price target of $127.54. The company's strong financial health and late-stage clinical programs may attract investor interest.
The increase in the average price target and positive adjustments by analysts suggest a bullish outlook for NBIX in the short term. The company's strong financial metrics and clinical programs are likely to be viewed positively by investors, potentially leading to a rise in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100